Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun.

This new trial will explore the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX in patients with advanced pancreatic cancer. FOLFIRINOX is widely used as the first-line treatment for pancreatic cancer patients in the US, as well as parts of Europe.

This trial will be run under the Investigational New Drug (IND) application for narmafotinib cleared by the US Food and Drug Administration (FDA) last year.

A multinational CRO has been engaged to coordinate and manage the trial, and manufacture of drug product for exclusive use in the trial has been completed.

Amplia CEO and MD Dr Chris Burns commented:

“We are extremely excited to have signed up a world-class CRO to coordinate running this trial and to have started engaging with trial sites. This represents an important next step in the development of narmafotinib by exploring the potential of the drug in combination with another widely used pancreatic cancer treatment.”

US clinical trial activities for narmafotinib now underway